ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Arima Genomics Announces New Partnership with Basepair to Accelerate Bioinformatics Analysis of 3D Genomics Data

Arima Genomics, Inc., the leader in 3D genomics, today announced a new partnership with Basepair to empower scientists with new options for bioinformatic analysis of 3D genomic data. The deal will make the Arima Genomics bioinformatics pipelines more accessible to bench scientists by making it available through a user-friendly interface, decreasing compute time, improving data handling and sharing, and generating easy-to-understand reports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221103005191/en/

Through this partnership, Arima will enable their customers with an initial integration of the Arima-SV bioinformatics pipeline through a white-labeled web portal powered by the Basepair platform. This portal will allow researchers to readily upload standard sequencing files using a point and click graphical user interface (GUI) and quickly identify structural variants from their 3D genomic data. In addition to providing secure file transfer and storage, this will substantially decrease the need for customers to invest in compute and bioinformatics resources.

"This partnership brings our customers more bioinformatics options and enables those without bioinformatics support to understand their data with an easy-to-use analysis tool," said Anthony Schmitt, PhD, SVP of Science at Arima Genomics. "Basepair will help us further democratize our 3D genomics solutions for elucidating genomic sequence and structure across a broader range of laboratories that do not always have dedicated bioinformatics capabilities."

"Basepair offers a range of automated pipelines for next-generation sequencing analysis and looks forward to enabling Arima's customers with faster and easier analysis of 3D genomics data," said Amit Sinha, PhD, Founder of Basepair. "We are confident that Arima Genomics' customers will find great value in our platform's ability to reduce compute time and generate meaningful insights from Arima data."

About Arima Genomics

Arima Genomics, Inc. is advancing life sciences research through the power of 3D genomics by providing unparalleled access to the sequence and structure of any genome. Arima Genomics offers the most advanced technologies for preserving the structural organization of the genome to drive discovery in genome biology and human health. To learn more, visit www.arimagenomics.com and connect with us on Twitter, LinkedIn, and YouTube.

About Basepair

Basepair, Inc. is the market leader in helping organizations maximize the potential of their own cloud, personnel, and genomic data resources to accelerate time to scientific insight in the biopharmaceutical, academic and genomic technologies industries. The easy-to-use interface, modern architecture, and novel pay-as-you-go licensing model enables scientists in organizations of all types and sizes to quickly analyze and make sense of a multitude of genomic data types, expedite the scientific discovery that leads to novel therapeutics and life-saving medicines. To learn more, visit www.basepairtech.com

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+0.00 (0.00%)
AAPL  268.47
+0.00 (0.00%)
AMD  233.54
+0.00 (0.00%)
BAC  53.20
+0.00 (0.00%)
GOOG  279.70
+0.00 (0.00%)
META  621.71
+0.00 (0.00%)
MSFT  496.82
+0.00 (0.00%)
NVDA  188.15
+0.00 (0.00%)
ORCL  239.26
+0.00 (0.00%)
TSLA  429.52
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.